Phase 1 Trial to Assess Safety and Immunogenicity of Self-replicating RNA (srRNA) Herpes Zoster Vaccine (JCXH-105)
Randomized, Double-Blinded, Placebo-Controlled Phase 1 Clinical Trial to Assess the Safety and Immunogenicity of Two Doses of Self-replicating RNA (srRNA) Herpes Zoster Vaccine (JCXH-105) in Healthy Participants
Herpes zoster is caused by reactivation of varicella zoster virus. This is a Phase 1 clinical trial to evaluate the safety and immunogenicity of self-replicating RNA (srRNA) herpes zoster vaccine JCXH-105. Eligible participants will receive 2 doses of study vaccine/placebo at planned dose levels and follow scheduled safety and immunogenicity follow-up visits. The goal of this study is to assess the safety profile and immune response induced by JCXH-105.
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
研究の種類
研究の種類
入学 (推定)
入学
段階
段階
- フェーズ 1
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
-
(1) Gender: Male or female; (2) Age: ≥ 40 years of age at screening. (3) Status: Healthy participants. (4) Subject agrees not to receive any other herpes zoster vaccine while participating in this study.
(5) All Laboratory values required for screening prior to study enrollment are within normal limits or abnormal without clinical significance as judged by the investigator.
(6) Female participants must meet the following criteria:
-
Surgically sterile or postmenopausal for ≥ 2 years, or women of childbearing potential (premenopausal or postmenopausal for < 2 years) who have a negative pregnancy test and are willing to use effective contraception from the first administration of investigational vaccine/placebo to 12 months after the full-course vaccination.
-
Agree not to breastfeed from the first administration of investigational vaccine/placebo to at least 3 months after the full-course vaccination.
(7) Male participants should meet the following criteria: agree to use effective contraception and not to donate sperms from the first administration of investigational vaccine/placebo to 12 months after the full-course vaccination.
(8) Able to fully understand and voluntarily sign the informed consent form.
-
Exclusion Criteria:
-
(1) Participants who have a history of herpes zoster or are currently diagnosed with herpes zoster, or have a history of chickenpox, or a history of close contact with chickenpox/herpes zoster patients within 30 days before enrollment.
(2) History of chickenpox or herpes zoster vaccination. (3) Hypersensitivity to any component of the investigational vaccine/placebo, or any previous serious reaction to vaccination, or a history of serious allergic disease.
(4) Fever within 3 days prior to enrollment, acute illness or acute exacerbation of chronic illness within 7 days prior to enrollment, or taking antipyretic, analgesic, and anti-allergic drugs within 3 days prior to enrollment.
(5) History of significant cardiac disease, or myocarditis or pericarditis. (6) At present, participants with severe liver and kidney diseases, spleen dysfunction or asplenia, hypertension that cannot be controlled by drugs, diabetes with serious complications and other chronic diseases are currently suffering.
(7) Use of whole blood, blood products, or immunoglobulins within 3 months prior to vaccination or planned use during the study.
(8) Has received any inactive vaccine within 14 days prior to the first dose of vaccine.
(9) Received the following within 28 days prior to the first dose of vaccine: Any live/mRNA vaccine; Immunomodulators or immunosuppressive drugs; Granulocyte colony-stimulating factor or granulocyte-macrophage colony-stimulating factor; Receiving systemic corticosteroids for 3 or more consecutive days. (Note: Study participants are permitted to receive long-term systemic prednisone at a dose ≤10 mg/day, or systemic corticosteroids equivalent to prednisone. Topical medications such as ointments, eye drops, inhalants or nasal sprays are allowed, provided that the topical medications should not exceed the recommended dose in the instructions and there are no signs of systemic exposure.) (10) Have confirmed or suspected immunosuppression, immunodeficiency, or autoimmune disease.
(11) Positive screening test for HIV antibodies, hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibodies.
(12) Known history of active or latent tuberculosis (Mycobacterium tuberculosis).
(13) Axillary temperature > 37.0 °C at enrollment. (14) Participation in another drug, device, or other vaccine clinical trial within 30 days prior to the first dose of investigational vaccine/placebo or planned participation during the study period.
(15) Participants with dermatologic condition that could affect local solicited adverse reaction assessments (e.g., tattoos, psoriasis, patches affecting skin over the deltoid area).
(16) Participants with contraindications to IM injection. (17) The investigator considers that there are other situations unsuitable for participating in this study, including but not limited to failure to participate in follow-up according to the study protocol.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:防止
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:トリプル
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
実験的:Low-dose JCXH-105
Participants receive low dose of JCXH-105 |
Self-replicating RNA (srRNA) Herpes Zoster Vaccine (JCXH-105) |
|
プラセボコンパレーター:Low-dose placebo
Participants receive low dose of placebo |
Placebo (sodium chloride injection) as control |
|
実験的:Medium-dose JCXH-105
Participants receive medium dose of JCXH-105 |
Self-replicating RNA (srRNA) Herpes Zoster Vaccine (JCXH-105) |
|
プラセボコンパレーター:Medium-dose placebo
Participants receive medium dose of placebo |
Placebo (sodium chloride injection) as control |
|
実験的:High-dose JCXH-105
Participants receive high dose of JCXH-105 |
Self-replicating RNA (srRNA) Herpes Zoster Vaccine (JCXH-105) |
|
プラセボコンパレーター:High-dose placebo
Participants receive high dose of placebo |
Placebo (sodium chloride injection) as control |
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Serious adverse events (SAEs)
時間枠:From Day 1 post- administration through 360 days after the full-course vaccination
|
Including frequency, severity, duration, and relationship to the investigational vaccine/placebo |
From Day 1 post- administration through 360 days after the full-course vaccination
|
|
Solicited local injection site adverse events
時間枠:Within 14 days after each dose of investigational vaccine/placebo
|
Including frequency, severity, duration, and relationship to the investigational vaccine/placebo |
Within 14 days after each dose of investigational vaccine/placebo
|
|
Solicited systemic adverse events
時間枠:Within 14 days after each dose of the investigational vaccine/placebo
|
Including frequency, severity, duration, and relationship to the investigational vaccine/placebo |
Within 14 days after each dose of the investigational vaccine/placebo
|
|
Unsolicited AEs
時間枠:Within 30 days after each dose of the investigational vaccine/placebo
|
Including frequency, severity, duration, and relationship to the investigational vaccine/placebo |
Within 30 days after each dose of the investigational vaccine/placebo
|
|
Laboratory parameters
時間枠:On the third day after each dose of the investigational vaccine/placebo
|
Clinically significant abnormal changes of laboratory parameters compared with pre-vaccination |
On the third day after each dose of the investigational vaccine/placebo
|
|
Adverse events of special interest (AESIs)
時間枠:From Day 1 post administration through 360 days after the full-course vaccination
|
Including frequency, severity, duration, and relationship to the investigational vaccine/placebo |
From Day 1 post administration through 360 days after the full-course vaccination
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (推定)
研究開始
一次修了 (推定)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
その他の研究ID番号
- JCXH-105-002
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
米国で製造され、米国から輸出された製品。
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。